Many people with advanced cervical cancer face a tough choice when their first treatment stops working. Doctors often worry that giving the same type of immune therapy again will not work. This trial looked at a different approach called immune rechallenge. It involves giving a drug called zimberelimab combined with lenvatinib to patients who had already received immune checkpoint inhibitor therapy.
The study involved 30 patients who had progressed on or after prior ICI therapy. ICI stands for immune checkpoint inhibitor, a common type of cancer treatment. The team found specific changes in the patients blood cells that seemed to match better outcomes. Responders showed more effector memory CD8+ T cells and reduced exhausted CD8+ T cells after treatment.
The findings are early and based on a small group of people. This single-arm trial design means there was no direct comparison group. However, the results highlight the potential feasibility of immune rechallenge. Spatiotemporal genomic and immunologic alterations are critical treatment biomarkers to identify responders. This helps doctors understand who might benefit from trying this specific combination again.